Teva to Relocate US Headquarters to New Jersey

Jul 11, 2018
By BioPharm International Editors

Teva Pharmaceuticals USA, the United States division of Teva Pharmaceutical Industries, will move its US headquarters from North Wales, PA, to Parsippany-Troy Hills, NJ.

The company will expand its existing Parsippany-Troy Hills location to nearly 350,000 square feet and expects to transfer and create 843 jobs while retaining 232 existing positions. According to Teva, the move will consolidate its operations into a more centralized location to drive efficiencies.

“While Teva will retain a significant presence in Pennsylvania, reducing the number of sites supports our drive to continue to improve productivity and efficiencies,” said Brendan O’Grady, executive vice president and head of North America Commercial, Teva Pharmaceuticals, in a July 5, 2018 statement issued by the Office of Phil Murphy, governor of New Jersey“We’re pleased to expand our presence in New Jersey, having closer proximity to a vibrant business hub and a dynamic life sciences environment—all while increasing jobs and preserving many existing roles.”

Teva Pharmaceutical Industries is a manufacturer of specialty and generic pharmaceuticals based in Israel that has a global product portfolio of more than 1800 molecules and a presence in 60 countries, including 30 locations across the US and its territories.

Source: Office of NJ Governor Phil Murphy

native1_300x100
lorem ipsum